logo-loader
viewCytoDyn Inc.

CytoDyn wins IRB approval to give leronlimab to triple-negative breast cancer patients on compassionate grounds

CEO Nader Pourhassan said the company is dedicated to advancing the therapeutic opportunity to many more patients in its ongoing trials

CytoDyn - CytoDyn wins IRB approval to give leronlimab to triple-negative breast cancer patients on compassionate grounds
CytoDyn received approval from the Institutional Review Board for its drug leronlimab to be given to TNBC patients under compassionate use, also known as the expanded access program

CytoDyn Inc (OTCMKTS:CYDY) said Wednesday that it has received approval from the Institutional Review Board for its drug leronlimab to be given to patients with triple-negative breast cancer (TNBC) under compassionate use, which is also known as the expanded access program. 

In a statement, the Vancouver, Washington-based late-stage biotechnology company said the program will allow TNBC patients who are not eligible under the ongoing Phase 1b/2 clinical trial to receive leronlimab (PRO 140). Under this protocol, patients with locally recurrent or metastatic triple-negative breast cancer who had progressed within six months or less on chemotherapy received leronlimab with a treatment of a physician’s choice. 

Significantly, the compassionate use or expanded access program is a potential pathway for patients with a life-threatening condition to gain access to an investigational medical product for treatment outside of clinical trials when no alternative therapy options are available.

READ: CytoDyn reports positive results from first patient in triple-negative breast cancer drug leronlimab trial 

The IRB is an appropriately constituted group that has been designated to review and monitor biomedical research involving people in step with regulations of the US Food and Drug Administration.

However, it is important to bear in mind that investigational drugs, biologics or medical devices haven’t yet been approved or cleared by the FDA.

“We are very pleased with the confidence demonstrated by the IRB to allow access to leronlimab for patients with triple-negative breast cancer. We are dedicated to advancing this therapeutic opportunity to many more patients in our ongoing trials,” said CytoDyn CEO Nader Pourhassan.

CytoDyn recently reported that the first patient of a new Phase 1b/2 clinical trial for its metastatic triple-negative breast cancer (mTNBC) treatment, leronlimab, reported encouraging initial results.

The biotechnology company said circulating tumor cells in the patient’s blood decreased significantly after leronlimab therapy at both two-week and five-week time points.

CytoDyn is developing leronlimab (PRO 140) to battle multiple diseases. Leronlimab has already completed nine clinical trials and been given to 800 patients in HIV treatment programs, Pourhassan said, without a single drug-related serious adverse event.

The drug itself works as an inhibitor of CCR5, a protein that plays a role in tumor invasion and metastasis. Blocking CCR5 has been shown to reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer.

Contact Uttara Choudhury at [email protected]

Follow her on Twitter: @UttaraProactive 

Quick facts: CytoDyn Inc.

Price: 0.292 USD

OTCQB:CYDY
Market: OTCQB
Market Cap: $113.37 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

CytoDyn shows value of company lies in their research and technology

CytoDyn (OTCMKTS:CYDY) President and CEO Nader Pourhassan and Chairman and Chief Medical Officer Dr Richard Pestell joined Proactive Investors' Steve Darling during the 9th Annual LD Micro Invitational Investor Conference in Los Angeles, CA.  Both talked about the company and where they...

on 4/6/19

2 min read